Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Proteon Therapeutics Inc (PRTO) USD0.001

Sell:$0.40 Buy:$0.43 Change: $0.0019 (0.46%)
NASDAQ:0.71%
Market closed |  Prices as at close on 22 July 2019 | Switch to live prices |
Sell:$0.40
Buy:$0.43
Change: $0.0019 (0.46%)
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
Market closed |  Prices as at close on 22 July 2019 | Switch to live prices |
Sell:$0.40
Buy:$0.43
Change: $0.0019 (0.46%)
Market closed |  Prices as at close on 22 July 2019 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company. The Company is focused on the development of pharmaceuticals to address patients with renal and vascular disease. The Company’s product candidate, vonapanitase, is a recombinant human elastase. The Company is developing vonapanitase to improve vascular access outcomes in patients with chronic kidney disease (CKD), undergoing or planning for hemodialysis.

Contact details

Address:
200 West St
WALTHAM
02451-1121
United States
Telephone:
+1 (781) 8900102
Website:
www.proteontherapeutics.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PRTO
ISIN:
US74371L1098
Market cap:
$8.13 million
Shares in issue:
19.59 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Timothy Noyes
    President, Chief Executive Officer, Director
  • George Eldridge
    Chief Financial Officer, Senior Vice President, Treasurer, Assistant Secretary,
  • E. Scott Toner
    Senior Vice President - Marketing
  • Steven Burke
    Senior Vice President, Chief Medical Officer
  • Matthew Kowalsky
    Vice President, Legal and Secretary
  • Daniel Gottlieb
    Vice President - Corporate Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a ISA, Lifetime ISA, SIPP or Fund & Share Account

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.